Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546780 · ClinicalTrials.gov registry record · Phase 3
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
A Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
- 19
- Study locations
NCT00546780: Completed Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT00546780 is a Phase 3 study of Multiple Myeloma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00546780, a Phase 3 study of Multiple Myeloma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG Tanespimycin
Study Locations (19)
California
- Comprehensive Blood And Cancer Center - Bakersfield
- Moores Ucsd Cancer Center - La Jolla
- University Of California Medical Center - San Francisco
Tennessee
- Tennessee Cancer Specialists - Knoxville
- Sarah Cannon Research Institute - Nashville
Colorado
- Rocky Mountain Cancer Centers - Denver
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Kansas
- University Of Kansas Medical Center - Westwood
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System Irb - Detroit
Missouri
- Capitol Comprehensive Cancer Care Center - Jefferson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00546780 record still lists
NCT00546780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.
NCT00546780 lists 19 locations in 16 states (California, Tennessee, Colorado).
Frequently Asked Questions
What is clinical trial NCT00546780 about?
NCT00546780 is a clinical study titled "A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse". This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
What is the current status of trial NCT00546780?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2008-02. Estimated completion is 2010-03.
What conditions does trial NCT00546780 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00546780?
The interventions under investigation include: Bortezomib (DRUG), Tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00546780?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00546780 being conducted?
This trial has 19 study locations across California, Colorado, Iowa, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00546780's enrollment target sits among peer trials
31 336th of 438 higher than 102 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia